We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
Teva Pharmaceutical and Xenon Pharmaceuticals announce top-line results in a Phase II study of topical TV-45070 in patients with post-herpetic neuralgia (PHN) did not meet the primary endpoint of a statistically significant change in pain from baseline to